How Halotestin Affects LDL Cholesterol

Fluoxymesterone (halotestin) raises LDL through the same route-dependent hepatic mechanism as the rest of the oral class, with no mitigating features:

1. 17-alpha-alkylation and first-pass hepatic exposure: This is the structural determinant Thompson (1989, PMID 2915439) isolated experimentally. Oral stanozolol raised LDL 29% while intramuscular testosterone in the same subjects lowered LDL 16%. Fluoxymesterone shares the oral 17-alpha-alkylated structure.

2. Extreme androgenic potency with no aromatisation: Fluoxymesterone is one of the most androgenic compounds in clinical use and does not convert to oestradiol. Because hepatic LDL receptor upregulation is an oestradiol-mediated effect, there is no counterbalance to androgen-driven receptor downregulation. Zmuda (1993, PMID 8487666) demonstrated that stripping oestradiol out of a testosterone protocol worsened every lipid endpoint measured; fluoxymesterone starts from that position.

3. Substantial hepatotoxicity: Fluoxymesterone carries a well-documented hepatotoxicity profile from its clinical era, when it was used for breast carcinoma and androgen deficiency. Heavy hepatic burden and disordered hepatic lipoprotein handling travel together in this class.

4. No published lipid measurement: Fluoxymesterone was largely displaced clinically before modern lipoprotein subfraction and apolipoprotein methods became routine, and it was never studied in the athletic dose ranges used today. Searching the literature for fluoxymesterone lipid or lipoprotein trials returns nothing usable. This is a genuine evidence gap, not an oversight.

There is no measured LDL figure for fluoxymesterone. No controlled trial in athletes, no modern lipid panel data at the doses used in strength sport.

What the class evidence supports:

• Glazer (1991, PMID 1929679) reported a weighted average LDL rise of 36% across the anabolic steroid literature.
• Thompson (1989, PMID 2915439) measured 29% from stanozolol at 6 mg/day, the closest structural analogue with data: a non-aromatising 17-alpha-alkylated oral.
• Webb (1984, PMID 6493049) documented an LDL to HDL ratio of 6.0 on oral-containing stacks versus 2.2 off.

Practical expectation at typical doses (10-40 mg/day):

• LDL up 30% or more within 3 to 4 weeks.
• HDL falling hard at the same time, given fluoxymesterone's androgenic potency and lack of oestrogenic offset.
• The LDL to HDL ratio is the number that will move most.

Use pattern matters: Halotestin is typically run for short blocks of 2 to 4 weeks before a competition or a strength attempt, often on top of an already lipid-hostile stack. The relevant question is usually not what halotestin does alone but what it adds to a profile that is already deteriorated.

Recovery: Reversible over roughly 8 to 12 weeks after stopping.

Baseline lipid and liver panel before the block: Halotestin blocks are short, so a baseline taken before the whole cycle rather than before the halotestin specifically will not tell you what the halotestin added.

On cycle:

• For a 2 to 4 week block, check at the end of week 2. Later than that and the block is over before you have the result.
• Track the LDL to HDL ratio and non-HDL cholesterol.
• Check ALT and AST at the same time. Fluoxymesterone is meaningfully hepatotoxic and the liver picture often moves first.

Stacking context: Halotestin is rarely the only lipid insult in play. If it is being added to a stack that already contains an oral, the panel will reflect the combination, and the compound to remove is whichever one is least essential to the goal.

Post-cycle: Recheck lipids and liver enzymes 8 weeks after the last dose.

Duration is the control:

• Keep halotestin blocks to 2 to 4 weeks. This is the standard usage pattern for good reason: both the hepatic and lipid costs escalate quickly.
• Do not stack a second 17-alpha-alkylated oral alongside it.

Supportive measures:

• Cardiovascular exercise 30 to 45 minutes, 4 to 5 times per week.
• Soluble fibre 10 to 25 g/day, which lowers LDL through bile acid sequestration and works independently of the hepatic receptor pathway the compound is disrupting.
• Replace saturated fat with unsaturated fat for the duration of the block.
• Omega-3 at 3 to 4 g/day addresses triglycerides rather than LDL.

Set expectations honestly: No supplement protocol offsets a non-aromatising 17-alpha-alkylated oral at strength-sport doses. The lipid cost of a halotestin block is paid; the question is only how long the exposure lasts.

Further reading: What steroids actually do to your cholesterol